Evaluation of pharmacokinetic/pharmacodynamic model-based optimized combination regimens against multidrug-resistant Pseudomonas aeruginosa in a murine thigh infection model by using humanized dosing schemes

Rajbharan Yadav, Jürgen B. Bulitta, Jiping Wang, Roger L. Nation, Cornelia B. Landersdorfer

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

We previously optimized imipenem and tobramycin combination regimens against a double-resistant clinical Pseudomonas aeruginosa isolate by using in vitro infection models, mechanism-based pharmacokinetic/pharmacodynamic modeling (MBM), and Monte Carlo simulations. The current study aimed to evaluate these regimens in a neutropenic murine thigh infection model and to characterize the time course of bacterial killing and regrowth via MBM. We studied monotherapies and combinations of imipenem with tobramycin in vivo against the double-resistant clinical P. aeruginosa isolate by using humanized dosing schemes. Viable count profiles of total and resistant populations were quantified over 24 h. Tobramycin monotherapy (7 mg/kg every 24 h [q24h] as a 0.5-h infusion) was ineffective. Imipenem monotherapies (continuous infusion of 4 or 5 g/day with a 1-g loading dose) yielded 2.47 or 2.57 log10 CFU/thigh killing at 6 h. At 24 h, imipenem at 4 g/day led to regrowth up to the initial inoculum (4.79 0.26 log10 CFU/thigh), whereas imipenem at 5 g/day displayed 1.75 log10 killing versus the initial inoculum. The combinations (i.e., imipenem at 4 or 5 g/day plus tobramycin) provided a clear benefit, with bacterial killing of 2.51 or 1.50 log10 CFU/thigh compared to the respective most active monotherapy at 24 h. No colonies were detected on 3MIC agar plates for combinations, whereas increased resistance (at 3MIC) emerged for monotherapies (except imipenem at 5 g/day). MBM suggested that tobramycin considerably enhanced the imipenem target site concentration up to 2.6-fold. The combination regimens, rationally optimized via a translational modeling approach, demonstrated substantially enhanced bacterial killing and suppression of regrowth in vivo against a double-resistant isolate and are therefore promising for future clinical evaluation.

Original languageEnglish
Article numbere01268
Number of pages11
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number12
DOIs
Publication statusPublished - 1 Dec 2017

Keywords

  • Imipenem
  • Mathematical modeling
  • Neutropenic thigh infection model
  • Pharmacodynamics
  • Population pharmacokinetics
  • Tobramycin

Cite this

@article{843234158a8144ac847dc26b8189ef79,
title = "Evaluation of pharmacokinetic/pharmacodynamic model-based optimized combination regimens against multidrug-resistant Pseudomonas aeruginosa in a murine thigh infection model by using humanized dosing schemes",
abstract = "We previously optimized imipenem and tobramycin combination regimens against a double-resistant clinical Pseudomonas aeruginosa isolate by using in vitro infection models, mechanism-based pharmacokinetic/pharmacodynamic modeling (MBM), and Monte Carlo simulations. The current study aimed to evaluate these regimens in a neutropenic murine thigh infection model and to characterize the time course of bacterial killing and regrowth via MBM. We studied monotherapies and combinations of imipenem with tobramycin in vivo against the double-resistant clinical P. aeruginosa isolate by using humanized dosing schemes. Viable count profiles of total and resistant populations were quantified over 24 h. Tobramycin monotherapy (7 mg/kg every 24 h [q24h] as a 0.5-h infusion) was ineffective. Imipenem monotherapies (continuous infusion of 4 or 5 g/day with a 1-g loading dose) yielded 2.47 or 2.57 log10 CFU/thigh killing at 6 h. At 24 h, imipenem at 4 g/day led to regrowth up to the initial inoculum (4.79 0.26 log10 CFU/thigh), whereas imipenem at 5 g/day displayed 1.75 log10 killing versus the initial inoculum. The combinations (i.e., imipenem at 4 or 5 g/day plus tobramycin) provided a clear benefit, with bacterial killing of 2.51 or 1.50 log10 CFU/thigh compared to the respective most active monotherapy at 24 h. No colonies were detected on 3MIC agar plates for combinations, whereas increased resistance (at 3MIC) emerged for monotherapies (except imipenem at 5 g/day). MBM suggested that tobramycin considerably enhanced the imipenem target site concentration up to 2.6-fold. The combination regimens, rationally optimized via a translational modeling approach, demonstrated substantially enhanced bacterial killing and suppression of regrowth in vivo against a double-resistant isolate and are therefore promising for future clinical evaluation.",
keywords = "Imipenem, Mathematical modeling, Neutropenic thigh infection model, Pharmacodynamics, Population pharmacokinetics, Tobramycin",
author = "Rajbharan Yadav and Bulitta, {J{\"u}rgen B.} and Jiping Wang and Nation, {Roger L.} and Landersdorfer, {Cornelia B.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1128/AAC.01268-17",
language = "English",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "1098-6596",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Evaluation of pharmacokinetic/pharmacodynamic model-based optimized combination regimens against multidrug-resistant Pseudomonas aeruginosa in a murine thigh infection model by using humanized dosing schemes

AU - Yadav, Rajbharan

AU - Bulitta, Jürgen B.

AU - Wang, Jiping

AU - Nation, Roger L.

AU - Landersdorfer, Cornelia B.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - We previously optimized imipenem and tobramycin combination regimens against a double-resistant clinical Pseudomonas aeruginosa isolate by using in vitro infection models, mechanism-based pharmacokinetic/pharmacodynamic modeling (MBM), and Monte Carlo simulations. The current study aimed to evaluate these regimens in a neutropenic murine thigh infection model and to characterize the time course of bacterial killing and regrowth via MBM. We studied monotherapies and combinations of imipenem with tobramycin in vivo against the double-resistant clinical P. aeruginosa isolate by using humanized dosing schemes. Viable count profiles of total and resistant populations were quantified over 24 h. Tobramycin monotherapy (7 mg/kg every 24 h [q24h] as a 0.5-h infusion) was ineffective. Imipenem monotherapies (continuous infusion of 4 or 5 g/day with a 1-g loading dose) yielded 2.47 or 2.57 log10 CFU/thigh killing at 6 h. At 24 h, imipenem at 4 g/day led to regrowth up to the initial inoculum (4.79 0.26 log10 CFU/thigh), whereas imipenem at 5 g/day displayed 1.75 log10 killing versus the initial inoculum. The combinations (i.e., imipenem at 4 or 5 g/day plus tobramycin) provided a clear benefit, with bacterial killing of 2.51 or 1.50 log10 CFU/thigh compared to the respective most active monotherapy at 24 h. No colonies were detected on 3MIC agar plates for combinations, whereas increased resistance (at 3MIC) emerged for monotherapies (except imipenem at 5 g/day). MBM suggested that tobramycin considerably enhanced the imipenem target site concentration up to 2.6-fold. The combination regimens, rationally optimized via a translational modeling approach, demonstrated substantially enhanced bacterial killing and suppression of regrowth in vivo against a double-resistant isolate and are therefore promising for future clinical evaluation.

AB - We previously optimized imipenem and tobramycin combination regimens against a double-resistant clinical Pseudomonas aeruginosa isolate by using in vitro infection models, mechanism-based pharmacokinetic/pharmacodynamic modeling (MBM), and Monte Carlo simulations. The current study aimed to evaluate these regimens in a neutropenic murine thigh infection model and to characterize the time course of bacterial killing and regrowth via MBM. We studied monotherapies and combinations of imipenem with tobramycin in vivo against the double-resistant clinical P. aeruginosa isolate by using humanized dosing schemes. Viable count profiles of total and resistant populations were quantified over 24 h. Tobramycin monotherapy (7 mg/kg every 24 h [q24h] as a 0.5-h infusion) was ineffective. Imipenem monotherapies (continuous infusion of 4 or 5 g/day with a 1-g loading dose) yielded 2.47 or 2.57 log10 CFU/thigh killing at 6 h. At 24 h, imipenem at 4 g/day led to regrowth up to the initial inoculum (4.79 0.26 log10 CFU/thigh), whereas imipenem at 5 g/day displayed 1.75 log10 killing versus the initial inoculum. The combinations (i.e., imipenem at 4 or 5 g/day plus tobramycin) provided a clear benefit, with bacterial killing of 2.51 or 1.50 log10 CFU/thigh compared to the respective most active monotherapy at 24 h. No colonies were detected on 3MIC agar plates for combinations, whereas increased resistance (at 3MIC) emerged for monotherapies (except imipenem at 5 g/day). MBM suggested that tobramycin considerably enhanced the imipenem target site concentration up to 2.6-fold. The combination regimens, rationally optimized via a translational modeling approach, demonstrated substantially enhanced bacterial killing and suppression of regrowth in vivo against a double-resistant isolate and are therefore promising for future clinical evaluation.

KW - Imipenem

KW - Mathematical modeling

KW - Neutropenic thigh infection model

KW - Pharmacodynamics

KW - Population pharmacokinetics

KW - Tobramycin

UR - http://www.scopus.com/inward/record.url?scp=85034743258&partnerID=8YFLogxK

U2 - 10.1128/AAC.01268-17

DO - 10.1128/AAC.01268-17

M3 - Article

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 1098-6596

IS - 12

M1 - e01268

ER -